Edwards Lifesciences (NYSE: EW) exec sells 1,500 common shares

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daveen Chopra, CVP, TMTT & Surgical, reported an open-market sale of 1,500 shares of common stock. The shares were sold at a weighted average price of $84.6035 per share in multiple trades between $84.6002 and $84.6050. Following this transaction, Chopra directly holds 44,324 shares of Edwards Lifesciences common stock.

Insider Trade Summary

Net Seller: 1,500 shares ($126,905)

Net Sell 1 txn

Insider Chopra Daveen

Role CVP, TMTT & Surgical

Sold 1,500 shs ($127K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,500	$84.6035	$127K

Holdings After Transaction: Common Stock — 44,324 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 1,500 shares Weighted average sale price: $84.6035 per share Price range of trades: $84.6002–$84.6050 per share +2 more

5 metrics

Shares sold 1,500 shares Open-market sale on 2026-05-22

Weighted average sale price $84.6035 per share Open-market sale of common stock

Price range of trades $84.6002–$84.6050 per share Multiple trades comprising reported sale

Shares held after transaction 44,324 shares Direct ownership following sale

Net shares sold 1,500 shares Net buy/sell direction from transaction summary

Key Terms

open-market sale, weighted average sale price, Common Stock, Form 4

4 terms

open-market sale financial

"reported an open-market sale of 1,500 shares of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"sold at a weighted average price of $84.6035 per share"

Common Stock financial

"open-market sale of 1,500 shares of common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The sale was disclosed on Form 4 and reflects a routine"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/23/2026 - 04:35 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chopra Daveen

(Last)

(First)

(Middle)

ONE EDWARDS WAY

(Street)

IRVINE

CALIFORNIA

92614

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CVP, TMTT & Surgical

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/22/2026		S		1,500	D	$84.6035⁽¹⁾	44,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $84.6002 to $84.6050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Edwards Lifesciences (EW) report for Daveen Chopra?

Edwards Lifesciences reported that executive Daveen Chopra sold 1,500 shares of common stock in an open-market transaction. The sale was disclosed on Form 4 and reflects a routine portfolio move by a company officer based on the information provided.

At what price did Daveen Chopra sell Edwards Lifesciences (EW) shares?

Daveen Chopra sold 1,500 Edwards Lifesciences shares at a weighted average price of $84.6035. The transaction occurred through multiple trades, with individual prices ranging from $84.6002 to $84.6050, as detailed in the Form 4 footnote.

How many Edwards Lifesciences (EW) shares does Daveen Chopra hold after the sale?

After selling 1,500 shares, Daveen Chopra directly holds 44,324 shares of Edwards Lifesciences common stock. This post-transaction holding figure comes directly from the Form 4 and shows his remaining equity stake in the company.

What role does Daveen Chopra hold at Edwards Lifesciences (EW)?

Daveen Chopra serves as Corporate Vice President, TMTT & Surgical at Edwards Lifesciences. His officer status makes his equity transactions reportable on Form 4, providing transparency into trades involving company insiders and their share ownership.

Was the Edwards Lifesciences (EW) insider sale executed in a single trade?

The insider sale was not a single trade. The Form 4 footnote states the 1,500-share sale was executed in multiple trades, with prices ranging from $84.6002 to $84.6050, and the reported $84.6035 figure is a weighted average sale price.